Mintayax (Pemetrexed)

Pemetrexed blocks several folate‑dependent enzymes that are essential for DNA and RNA synthesis, such as thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. By inhibiting these pathways, the drug prevents tumor cells from replicating their genetic material, leading to cell cycle arrest and apoptosis.

The dose of Mintayax is individualized by the prescribing oncologist based on factors such as the patient’s body surface area, renal function, liver function, and overall treatment plan. The prescriber calculates the appropriate amount for each infusion cycle and adjusts it as needed throughout therapy.

The safety of Mintayax in pregnancy and lactation has not been established. It is generally contraindicated in pregnant or nursing women because of potential fetal toxicity and the risk of adverse effects on the infant. Women of child‑bearing potential should use effective contraception during treatment and for a period thereafter as advised by their physician.

To order Mintayax, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and any necessary import documentation.

Compared with older antifolates such as methotrexate, pemetrexed (Mintayax) has a broader enzyme inhibition profile and is specifically approved for mesothelioma and non‑squamous NSCLC. Clinical studies have shown improved response rates and survival in these indications, although both drug classes share similar myelosuppressive and renal toxicity risks that require monitoring.

Mintayax must be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and do not freeze or shake the solution. If the product reaches room temperature for a short period, it may be used immediately, but it should be returned to refrigerated conditions as soon as possible.

Mintayax is supplied as an injectable solution for intravenous infusion. It is administered by a qualified healthcare professional, usually over a period of 10 minutes to 1 hour depending on the prescribed protocol. The infusion is given in a clinical setting where vital signs and infusion reactions can be monitored.

The most serious risks include severe neutropenia, thrombocytopenia, interstitial lung disease, acute renal failure, and anaphylactic reactions. Patients should be monitored closely for signs of infection, bleeding, respiratory distress, sudden changes in kidney function, or allergic symptoms, and treatment should be adjusted or discontinued if these events occur.

Mintayax should not be used in patients with known hypersensitivity to pemetrexed or any component of the formulation. It is also contraindicated in individuals with severe renal impairment (creatinine clearance < 45 mL/min) or uncontrolled liver disease, and caution is advised for patients with pre‑existing lung conditions.